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The use of highly active antiretroviral therapy (HAART)
in the treatment of human immunodeficiency virus type 1
(HIV-1)-infected individuals has dramatically changed the
clinical outcome of many infected persons, contributing to
the current substantial declines in both the incidence of AIDS
and AIDS-related mortality (1). However, replication-com-
petent virus, HIV-1 proviral DNA, spliced and unspliced
HIV-1 RNA in CD4+ T cells, and unidentified viral reser-
voirs have all been observed in most infected individuals, even
when plasma viremia has been suppressed below detectable
levels (2, 3). In addition, HAART does not prevent replica-
tion in cells harboring competent HIV-1 proviral DNA.
These facts underline the impossibility of eradicating HIV-
1 using HAART alone (2, 4). 
The quantitative determination of HIV-1 proviral DNA
load offers significant therapeutic information, especially
when HIV-RNA levels drop below detectable limits during
HAART treatment (5). However, the clinical factors associ-
ated with proviral DNA load have not been elucidated. Some
factors, such as CD4+ T cell counts or the CD4+:CD8+ T
cell ratio, represent potential clinical variables associated with
HIV-1 proviral DNA load (6).
The objective of this study was to evaluate clinical factors
associated with HIV-1 proviral DNA load in HIV-1-infect-
ed individuals on HAART who have undetectable plasma
viral RNA.
Thirty-six HIV-1-infected persons who had been admit-
ted to a tertiary-care teaching hospital were enrolled in this
study after they gave informed consent. All subjects were
chronically HIV-1 infected patients with undetectable plas-
ma viral loads on HAART. We reviewed the medical record
of each patient retrospectively, collecting age, sex, CD4+ T
lymphocyte counts, CD8+ T lymphocyte counts, levels of
plasma viral RNA, regimens and durations of antiretroviral
treatments, and opportunistic diseases, among others. Data
at various times of each patients were collected. The collect-
ed data contained the mean level of plasma viral RNA when
CD4+ T cell counts were above 500 cells/μ L without HAART.
HIV RNA levels were measured by nucleic acid sequence-
based amplification using a NucliSens
�ﬁEasyQ Analyzer
(Biomerieux, Boxtel, Netherlands). CD4+ and CD8+ T lym-
phocyte counts were calculated by multiplying the number
of lymphocytes measured with an automatic cell counter by
the percentage of CD4+ or CD8+ antigen-positive cells quan-
tified with monoclonal antibodies (Becton-Dickinson, New
Jersey, U.S.A.).
Peripheral blood mononuclear cells (PBMCs) were obtained
by Ficoll-Hypaque density gradient centrifugation. CD4+
152
Jun Yong Choi, Young Goo Song, 
Young Hwa Kim, Chang Oh Kim, 
Myung Soo Kim, Bum Sik Chin, 
Sang Hoon Han, Suk Hoon Choi, 
Han Sung Lee, Su Jin Jeong, 
Heekyoung Choi, and June Myung Kim
Department of Internal Medicine and AIDS Research
Institute, BK21 Project for Medical Sciences, Yonsei
University College of Medicine, Seoul, Korea
Address for correspondence
June Myung Kim, M.D.
Department of Internal Medicine, Yonsei University
College of Medicine, 134 Shinchon-dong, 
Seodaemun-gu, Seoul 120-752, Korea
Tel : +82.2-2228-1946, Fax : +82.2-393-6884
E-mail : jmkim@yuhs.ac
*This work was supported by Yonsei University
Research Fund of 2005. 
J Korean Med Sci 2009; 24: 152-4
ISSN 1011-8934
DOI: 10.3346/jkms.2009.24.1.152
Copyright � The Korean Academy
of Medical Sciences
Factors Associated with HIV-1 Proviral DNA Loads in Patients
with Undetectable Plasma RNA Load
To evaluate factors associated with human immunodeficiency virus type 1 (HIV-1)
proviral DNA load, we conducted a cross-sectional study of 36 chronically HIV-1-
infected individuals with undetectable plasma viral RNA. We used real-time poly-
merase chain reaction to determine the number of HIV-1 proviral DNA copies per
10
6 peripheral blood mononuclear cells. The mean level of plasma viral RNA when
the CD4+ T cell count was above 500 cells/μ L without highly active antiretroviral
therapy (HAART) was significantly associated with proviral DNA load at the time of
undetectable plasma HIV RNA with HAART. Strategies to reduce the level of plas-
ma viral RNA when patients’ CD4+ T cell counts are above 500 cells/μ L without
HAART could help reduce HIV-1 proviral DNA load.  
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T cells were isolated from PBMCs using a human CD4 cell-
separation kit (EasySepTM, StemCell Technologies, Vancou-
ver, Canada). Real-time polymerase chain reaction (PCR) was
used to determine the number of HIV-1 proviral DNA copies
per 106 PBMCs, as described elsewhere (6). The primers 5′ -
GGTCTCTCTGGTTAGACCAGAT-3′(5′ primer) and
5′ -CTGCTAGAGATTTTCCACACTG-3′ (3′ primer) were
used, along with the fluorescent probe, 5′ -6FAM-AGTAG-
TGTGTGCCCGTCTGTTTAMRA-3′ . PCR conditions
consisted of a denaturation step at 95℃ for 3 min, followed
by 45 cycles of 15 sec at 95℃ and 1 min at 58℃. Serially
diluted ACH-2 DNA was also subjected to PCR, as above,
to obtain standard curves. 
The independent t-test and Spearman’s rank correlation
were used to measure the correlation between HIV-1 provi-
ral DNA load and immunologic, virologic, and clinical param-
eters. To identify independent relationships between HIV-1
proviral DNA load and various factors, multivariate linear
regression analysis was performed with age, gender, CD4+
T cell count, and the variables that had a significant correla-
tion with HIV-1 proviral DNA load on univariate analysis.
All p values were 2-tailed, and p<0.05 was considered statis-
tically significant. All analyses were performed using SPSS
for Windows 12.0 (SPSS, Chicago, IL, U.S.A.).
The mean age of enrolled patients was 42.5±9.3 yr.
Among the patients, 47.2% were AIDS patients. The mean
follow-up duration of the subjects was 1,330±1,178 days,
and the years of diagnosis of HIV infection were 1991, 1994,
1997, 1999, 2000, 2001, 2002, and 2003 in 1, 2, 2, 5, 3,
2, 6, 8, and 7 patients, respectively. The mean CD4+ T cell
count was 431±201 cells/μ L, and the mean value of the mean
plasma viral RNA level when the CD4+ T cell count was
above 500 cells/μ L without HAART was 103,168±179,952
copies/mL. 
The mean HIV-1 proviral DNA load in all subjects was
2,968±4,956 copies/106 PBMCs. Among the examined
clinical parameters, only the mean level of plasma viral RNA
when the CD4+ T cell count was above 500 cells/μ L with-
out HAART was significantly associated with proviral DNA
load (Table 1, 2, p<0.05). There was no significant correla-
tion between proviral DNA load and CD4+ T cell count or
duration of HAART. Other clinical factors such as CD4+:
CD8+ T cell ratio, nadir CD4+ T cell count, age, or sex were
also not associated with HIV-1 proviral DNA load. Multi-
variate linear regression analysis revealed the mean level of
plasma viral RNA when the CD4+ T cell count was above
500 cells/μ L without HAART was significantly associated
with proviral DNA load (β =0.440, p=0.014).
The qualitative and quantitative evaluation of both serum
HIV-1 RNA genome and HIV-1 proviral DNA are pivotal
markers in the diagnosis and prognosis of HIV-1 infection
(7, 8). Although the quantitative determination of plasma
HIV RNA copies directly represents viral replication and is
the main prognostic parameter for disease progression (9),
the HIV-1 proviral DNA load represents the infection reser-
voir in PBMC and lymphoid tissues and plays a pivotal role
in immune surveillance escape (2, 10). The amount of provi-
ral DNA might also be an important virological marker for
exploring viral reservoirs and assessing the impact of treat-
ment (5). Moreover, the presence of this reservoir indicates
the possibility of a viral replication rebound when therapy
is interrupted or discontinued (2, 10). 
In one study, a significant inverse correlation was demon-
Variable
HIV-1 proviral DNA load  
(copies/10
6 PBMCs)
p value
Sex 0.697
Male (n=32) 2,852±4,721
Female (n=4) 3,896±7,416
CD4+ T cell counts (cells/μ L) 0.654
≥500 (n=22) 3,270±4,60
<499 (n=14) 2,494±5,099
CD4+:CD8+ T cell ratio 0.647
≥0.8 3,482±5,195
<0.8 2,678±4,911
AIDS 0.867
AIDS patients (n=17) 2,819±5,202
Non-AIDS patients (n=19) 3,102±4,866
HAART duration 0.891
1 yr (n=22) 2,876±4,616
<1 yr (n=14) 3,114±5,629
Mean level of plasma viral RNA  0.037
when the CD4+ T cell count 
was above 500 cells/μ L without 
HAART (copies/mL)
≥50,000 (n=16) 6,023±6,517
<50,000 (n=20) 1,403±3,207
Nadir CD4+ T cell counts (cells/μ L) 0.462
≥200 (n=20) 3,659±5,618
<200 (n=16) 2415±4,428
Table 1. Factors associated with HIV-1 proviral DNA load in 36
HIV-1 infected patients with suppressed plasma viral loads;
univariate analysis
Variable
Correlation
coefficient
p value
Age -0.073 0.671
CD4+ T cell counts (cells/μ L) -0.127 0.461
CD4+:CD8+ T cell counts ratio 0.095 0.587
HAART duration -0.106 0.551
Mean level of plasma viral RNA when the  0.351 0.049
CD4+ T cell count was above 500 cells/μ L
without HAART (copies/mL)
Nadir CD4+ T cell counts (cells/μ L) -0.149 0.384
Table 2. Correlation between various clinical factors and HIV-1
proviral DNA load in 36 HIV-1 infected patients with suppressed
plasma viral RNA; univariate analysis
HAART, highly active antiretroviral therapy.  HAART, highly active antiretroviral therapy.154 J.Y. Choi, Y.G. Song, Y.H. Kim, et al.
strated between the frequency of HIV-1 proviral DNA-bear-
ing CD4+ T cells and CD4+ T cell count (11). A similar
pattern was discovered for the CD4+:CD8+ T cell ratio of
HIV-1 infected individuals receiving HAART in whom plas-
ma viremia had been suppressed below the limit of detec-
tion for prolonged periods of time (6). CD8+ T cells also
appear to exhibit potent suppressive activity against HIV
replication in the latent viral reservoir via direct cellular con-
tact in patients who are naturally long-term nonprogressors
or in those treated with HAART (12). Other antiviral activ-
ities of CD8+ T cells may be responsible for the suppression
of HIV replication in the resting CD4+ T cell reservoirs (12). 
In this study, there was a significant correlation between
proviral DNA load at the time of undetectable plasma HIV
RNA with HAART and the mean level of plasma viral RNA
when the CD4+ T cell count was above 500 cells/μ L with-
out HAART. The mean levels of plasma viral RNA along
with CD4+ T lymphocyte counts above 500 cells/μ L could
reflect the size and quantity of viral reservoirs. 
The threshold level of plasma viral RNA for the predic-
tion of progression of HIV infection is not well defined. We
arbitrarily chose 50,000 copies/mL as the cut-off, because in
this study a plasma viral RNA load of 50,000 copies/mL
effectively divided the subjects into two groups with higher
or lower plasma viral RNA.
This study is limited by the fact that it features cross-sec-
tional findings in a small number of subjects. We collected
retrospective data without knowing the date of seroconver-
sion, and so we could not consider certain factors that affect
the progression of HIV infected patients for multivariate anal-
ysis. And, the mean level of plasma viral RNA when the
CD4+ T cell count was above 500 cells/μ L could be influ-
enced by the progression patterns of subjects and the frequen-
cy of the test, and it could not reflect the progression patterns
of each patient. 
In conclusion, we found evidence that the mean level of
plasma viral RNA when the CD4+ T cell count was above
500 cells/μ L without HAART may be associated with HIV-
1 proviral DNA load at the time of undetectable plasma HIV
RNA with HAART, potentially representing the size of viral
reservoirs. Strategies to reduce the levels of plasma viral RNA
when CD4+ T cell counts are above 500 cells/μ L without
HAART could help reduce HIV-1 proviral DNA loads.
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